Key facts
- Stately Bio’s last known valuation is $47.0M (Apr 2025).
- It has raised $12.0M; the latest was Seed Round ($12.0M) in Apr 2025.
- Notable investors include Village Global, Caffeinated Capital, Jeff Dean, Foothill Ventures, AIX Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Stately Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Stately Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stately Bio
Developer of regenerative medicine technologies designed for therapeutic discovery and manufacturing. The company's platform utilizes a patented machine learning-based live-cell imaging system that measures cell identity, behavior and maturation without labels or dyes, enabling the biotechnology and pharmaceutical sectors to advance cell therapy innovation through non-invasive, real-time analysis of living cells.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2022
- Employees
- 8
- Website
- statelybio.com/
- Ownership
- Privately Held (backing)
Stately Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stately Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stately Bio in its N-PORT filings yet. We sweep new filings monthly.